Beijing SL Pharm to Form JV to Serve Tumor Cure Market     

Beijing SL Pharmaceutical Co., Ltd. (SZ: 002038) announced on March 6th to form a joint venture in Liaoning province to produce tumor diagnosis pharmaceutical products.
   Beijing SL Pharm plans to invest RMB10.2 million in the joint venture, for the 51% stake.
   The proposed joint venture named Liaoning Maidi Biology Sci-Tech Co., Ltd. is aiming at producing pharmaceuticals for tumor diagnosis and cure and providing solutions in this field.
   The company said the move is to strengthen its medical services with a response to the domestic medical system reform and extend sales network as well as raise the profit-making ability.
   The joint venture is subject to approval by regulating authorities.
   Beijing SL Pharm focuses on the R & D, the production and sales of genic pharmaceuticals.